NYSE:LLYPharmaceuticals
Will Foundayo’s UK GLP‑1 Approval and New R&D Deals Change Eli Lilly's (LLY) Narrative?
In recent days, Eli Lilly announced multiple R&D agreements, including global rights to AlzeCure’s preclinical Alzheimer’s candidate ACD680 with potential milestones above US$1.00 billion, an ion channel collaboration with OmniAb, and a taRNA vaccine partnership with Amplitude Therapeutics, while also securing UK approval of its once-daily oral GLP‑1 drug Foundayo for weight management and type 2 diabetes.
These deals and the Foundayo approval deepen Lilly’s presence in obesity,...